K. Tewari, B. Monk, I. Vergote, A. Miller, A. de Melo, H. Kim, Y. Kim, A. Lisyanskaya, V. Samouélian, D. Lorusso, F. Damian, C-L. Chang, E. Gotovkin, Shin-ichiro Takahashi, D. Ramone, J. Pikiel, J. Li, M. Mathias, M. Fury, A. Oaknin
{"title":"Empower-cervical 1/GOG-3016/ENGOT-CX9:治疗复发/转移性宫颈癌的3期临床试验结果:cemiplimab vs研究者选择的化疗方案","authors":"K. Tewari, B. Monk, I. Vergote, A. Miller, A. de Melo, H. Kim, Y. Kim, A. Lisyanskaya, V. Samouélian, D. Lorusso, F. Damian, C-L. Chang, E. Gotovkin, Shin-ichiro Takahashi, D. Ramone, J. Pikiel, J. Li, M. Mathias, M. Fury, A. Oaknin","doi":"10.1136/ijgc-2021-igcs.1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19692,"journal":{"name":"Oral abstracts","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma\",\"authors\":\"K. Tewari, B. Monk, I. Vergote, A. Miller, A. de Melo, H. Kim, Y. Kim, A. Lisyanskaya, V. Samouélian, D. Lorusso, F. Damian, C-L. Chang, E. Gotovkin, Shin-ichiro Takahashi, D. Ramone, J. Pikiel, J. Li, M. Mathias, M. Fury, A. Oaknin\",\"doi\":\"10.1136/ijgc-2021-igcs.1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19692,\"journal\":{\"name\":\"Oral abstracts\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2021-igcs.1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma